

SHARING THE OUTCOMES AND USER EXPERIENCE FROM INDIA IN THE FIRST 750 TYPE 2 DIABETES PATIENTS WITH THE NEW LIBRE PRO 14-DAY GLUCOSE SENSOR



#108-L

JOTHYDEV KESAVADEV, LAKSHMY RAMACHANDRAN, ARUN SHANKAR, ASHWIN DAVID, GOPIKA KRISHNAN, SHEEJA SRINIVAS, ANNIE AJAI, GEETHU SANAL, SUNITHA JOTHYDEV

JOTHYDEV'S DIABETES & RESEARCH CENTERS, TRIVANDRUM & KOCHI, INDIA www.research.jothydev.com, jothydev@gmail.com

BACKGROUND

Frequent glucose monitoring imparts commendable benefits for a successful diabetes management. It facilitates optimal treatment decisions as well as instils patients with improved diabetes-self-care practices. Here we share our experience regarding the clinical utility of a novel continuous glucose monitoring system FreeStyle Libre Pro (FSLP), among our first 750 FSLP deployed T2DM patients. In contrast to the earlier devices, FSLP comes with several salient features such as extended sensor wear time, provides a collated glucose report, requires no patient interaction or finger-prick calibration, is totally pain-free and user-friendly. We have a well trained and dedicated diabetes management team consisting of clinicians, diabetes educators, dieticians, nurses, pharmacists and device technicians at our comprehensive diabetes centre that supports patients to achieve better treatment outcomes.

AIMS

FreeStyle Libre Pro, is the first ever retrospective CGM with a factory calibrated sensor. Clinical outcomes of T2DM patients deployed with FSLP were analysed and experiences evaluated.

METHODS

A retrospective analysis of the clinical data was done among our first 425 T2DM patients who were successfully deployed with FSLP. Experiences recounted (n=750) in terms of user friendliness, acceptability and sensor failure were evaluated.


RESULTS


Significant clinical improvements were noted in FSLP group (Table). Majority recounted a positive experience with FSLP (Figure: 1A). Reasons for sensor failures were identified (Figure: 1B).

CONCLUSIONS

FSLP led to clinical improvements and was widely appreciated. These benefits come at the cost of extra time and efforts spent in analyzing, interpreting and translating the findings into therapeutic and behavioural modifications.

TABLE IMPROVEMENTS IN THE CLINICAL PROFILE		
OF T2DM PATIENTS (N=425) AT 6 MONTHS		
BASELINE CHARACTERISTICS	FSLP GROUP	CONTROL GROUP
Age (years)	55.06 ± 13.48; 70.59% male	56.42 ± 10.08y; 75.41% male
T2DM duration(years)	13.89 ± 8.31	12.96 ± 7.84
On OHAs (%)	38.11%	39.71%
Insulin+OHAs (%)	61.89	60.29
CLINICAL PARAMETERS	FSLP GROUP - BASELINE CHANGE, P VALUE	CONTROL GROUP - BASELINE CHANGE, P VALUE
HbA1c %	-0.37, < 0.0001	-0.11, 0.074
FBS (mg/dL)	-13.76, < 0.0001	-2.99, 0.1682
PPBS (mg/dL)	-3.2, 0.1209	+14.87, 0.0361
BMI (kg/m²)	-0.2, 0.0325	-0.14, 0.3729
WC (cm)	-0.02, 0.9267	-0.17, 0.6514
TDD (U)	-0.22, 0.5353	+1.51, 0.0202





REFERENCES

- **1.** Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015 Nov;17(11):787-94.
- 2. Kesavadev J, Shankar A, Pillai PBS, Ashok AD, Sanal G, et al. Comparing iPro2 with Libre for Sensor Accuracy and User Friendliness. Diabetes Technol Ther. February 2016; 18(S1), A-1-A-139.
- **3.** Kesavadev J, Pillai PBS, Shankar A, Ashok AD, Sanal G, et al. Comparison of the New Factory Calibrated Sensor with Existing CGM Sensor. Diabetes. 2016; 65 (suppl 1), http://diabetes.diabetesjournals.org/content/65/Supplement_1. Accessed 29.05.17.